Processa Pharmaceuticals (PCSA) Price & Analysis

Compare

259 Followers

PCSA Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.15 - $1.50

Previous CloseN/A

Volume113.34K

Average Volume (3M)4.43M

Market Cap

$8.65M

Enterprise Value-$3.72M

Total Cash (Recent Filing)$6.94M

Total Debt (Recent Filing)$25.58K

Price to Earnings (P/E)―

Beta1.17

Next Earnings

Nov 05, 2025

EPS Estimate

-0.08

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.25

Shares Outstanding50,349,148

10 Day Avg. Volume2,614,364

30 Day Avg. Volume4,425,571

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap-0.43

Enterprise Value/Revenue-0.30

Enterprise Value/Gross Profit-1.32

Enterprise Value/Ebitda0.29

Forecast

1Y Price Target

$1.00

Price Target Upside455.56% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Clinical DevelopmentProcessa Pharmaceuticals is designing a new adaptive pivotal PCS499 Phase 3 study for kidney disease, based on preliminary positive results.

Licensing DealProcessa has signed a binding term sheet with Intact Therapeutics, granting an exclusive option to license PCS12852 and is eligible for up to $454M in milestone payments, a 12% royalty, and a 3.5% equity stake.

Strategic InvestmentProcessa recently announced that it secured a strategic investment and is evaluating corporate cryptocurrency treasury strategies as part of its broader financial and growth objectives.

Bears Say

Cash Balance ConcernsThe cash balance is not believed to be sufficient to complete the Phase 2 trial, posing a risk of delays for the interim analysis.

Financial ConstraintsAnalyst maintains a Hold rating due to capital constraints and challenging financing conditions that might limit the ability to complete the ongoing Phase 2 trial.

Stock Price ComplianceProcessa has received a notice from the NASDAQ exchange indicating that it is not currently in compliance with the minimum bid price requirement due to the low current share price.

Processa Pharmaceuticals News

Processa Pharmaceuticals price target lowered to $1 from $2 at H.C. Wainwright

H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on Processa Pharmaceuticals (PCSA) to $1 from $2...

8d ago

PCSA

Processa Pharmaceuticals Adjourns Special Shareholder Meeting

Processa Pharmaceuticals ( ($PCSA) ) has shared an announcement. On September 2, 2025, Processa Pharmaceuticals, Inc. held a...

7d ago

PCSA

Processa Pharmaceuticals Relocates 2025 Stockholder Meeting

Processa Pharmaceuticals ( ($PCSA) ) has issued an announcement. On August 25, 2025, Processa Pharmaceuticals, Inc. announced a...

15d ago

PCSA

Processa Pharmaceuticals Reports Increased Losses Amid Strategic Developments

Processa Pharmaceuticals, Inc. ( ($PCSA) ) has released its Q2 earnings. Here is a breakdown of the information...

1M ago

PCSA

Processa Pharmaceuticals Raises $1.3M in Private Placement

The latest update is out from Processa Pharmaceuticals ( ($PCSA) ). On August 4, 2025, Processa Pharmaceuticals entered...

1M ago

PCSA

Processa secures strategic investment, evaluates crypto strategy

Processa Pharmaceuticals (PCSA) announced that it has secured a strategic investment and that it is evaluating corporate cryptocurrency...

1M ago

PCSA

Processa Pharmaceuticals Files Prospectus for Stock Sale

Processa Pharmaceuticals ( ($PCSA) ) has provided an announcement. On July 25, 2025, Processa Pharmaceuticals filed a prospectus...

2M ago

PCSA

Processa Pharmaceuticals Approves Key Proposals at Annual Meeting

The latest update is out from Processa Pharmaceuticals ( ($PCSA) ). On July 18, 2025, Processa Pharmaceuticals held...

2M ago

PCSA

Processa Pharmaceuticals Reschedules Annual Shareholder Meeting

Processa Pharmaceuticals ( ($PCSA) ) has provided an announcement. On June 30, 2025, Processa Pharmaceuticals, Inc. held its...

2M ago

PCSA

Strategic Focus and Growth Potential Drive Buy Rating for Processa Pharmaceuticals

Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Processa Pharmaceuticals and keeping the price target...

2M ago

PCSA

Processa Pharmaceuticals Announces Strategic Portfolio Review

The latest update is out from Processa Pharmaceuticals ( ($PCSA) ). On July 1, 2025, Processa Pharmaceuticals announced...

2M ago

PCSA

Processa terminates license agreement for PCS3117

Processa Pharmaceuticals (PCSA) provides updates on its product pipeline, upcoming milestones and business activities. Key Portfolio Updates: PCS6422:...

2M ago

PCSA

Processa Pharmaceuticals Adjourns Annual Shareholder Meeting

Processa Pharmaceuticals ( ($PCSA) ) has provided an update. On June 30, 2025, Processa Pharmaceuticals held its Annual...

2M ago

PCSA

Processa Pharmaceuticals price target lowered to $2 from $6 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Processa Pharmaceuticals (PCSA) to $2 from $6 and keeps a...

2M ago

PCSA

PCSA FAQ

What was Processa Pharmaceuticals’s price range in the past 12 months?

Processa Pharmaceuticals lowest stock price was $0.15 and its highest was $1.50 in the past 12 months.

What is Processa Pharmaceuticals’s market cap?

Processa Pharmaceuticals’s market cap is $8.65M.

When is Processa Pharmaceuticals’s upcoming earnings report date?

Processa Pharmaceuticals’s upcoming earnings report date is Nov 05, 2025 which is in 56 days.

How were Processa Pharmaceuticals’s earnings last quarter?

Processa Pharmaceuticals released its earnings results on Aug 07, 2025. The company reported -$0.25 earnings per share for the quarter, missing the consensus estimate of -$0.22 by -$0.03.

Is Processa Pharmaceuticals overvalued?

According to Wall Street analysts Processa Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Processa Pharmaceuticals pay dividends?

Processa Pharmaceuticals does not currently pay dividends.

What is Processa Pharmaceuticals’s EPS estimate?

Processa Pharmaceuticals’s EPS estimate is -0.08.

How many shares outstanding does Processa Pharmaceuticals have?

Processa Pharmaceuticals has 50,349,148 shares outstanding.

What happened to Processa Pharmaceuticals’s price movement after its last earnings report?

Processa Pharmaceuticals reported an EPS of -$0.25 in its last earnings report, missing expectations of -$0.22. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Processa Pharmaceuticals?

Currently, no hedge funds are holding shares in PCSA

Company Description

Processa Pharmaceuticals

Processa Pharmaceuticals (PCSA) is a clinical-stage biopharmaceutical company focused on developing innovative drug products to address unmet medical needs. Operating primarily in the biopharmaceutical and healthcare sectors, the company is committed to advancing its pipeline of promising drug candidates through various stages of clinical development to ultimately improve patient outcomes.

Processa Pharmaceuticals (PCSA) Earnings & Revenues

Historic Earnings Reports

PCSA Stock 12 Month Forecast

Average Price Target

$1.00

▲(455.56% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","1":"$1","2":"$2","3":"$3","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$1.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$1.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0,1,2,3],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.19,0.25230769230769234,0.31461538461538463,0.3769230769230769,0.43923076923076926,0.5015384615384615,0.5638461538461539,0.6261538461538463,0.6884615384615385,0.7507692307692309,0.813076923076923,0.8753846153846154,0.9376923076923078,{"y":1,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.19,0.25230769230769234,0.31461538461538463,0.3769230769230769,0.43923076923076926,0.5015384615384615,0.5638461538461539,0.6261538461538463,0.6884615384615385,0.7507692307692309,0.813076923076923,0.8753846153846154,0.9376923076923078,{"y":1,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.19,0.25230769230769234,0.31461538461538463,0.3769230769230769,0.43923076923076926,0.5015384615384615,0.5638461538461539,0.6261538461538463,0.6884615384615385,0.7507692307692309,0.813076923076923,0.8753846153846154,0.9376923076923078,{"y":1,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.09,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.09,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.33,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.15,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.06,"date":1733011200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.88,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.55,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.41,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.25,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.3,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.2,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.21,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.19,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >